Evidence map›Paper›PMID 37884794›Full record

ArticleNature biomedical engineering2024

An injectable and biodegradable zwitterionic gel for extending the longevity and performance of insulin infusion catheters.

Ershuai Zhang, Yuanjie Shi, Xiangfei Han, Hui Zhu, Boyi Song, Chengbiao Yang, Zhiqiang Cao

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Ionic-Bionic Interfaces: Advancing Iontronic Strategies for Bioelectronic Sensing and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Recent advances in oral insulin delivery technologies.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ershuai ZhangDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA.ORCID http://orcid.org/0000-0001-6866-2762
Yuanjie ShiDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA.
Xiangfei HanDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA.ORCID http://orcid.org/0000-0003-0168-657X
Hui ZhuDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA.ORCID http://orcid.org/0000-0002-8601-669X
Boyi SongDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA.
Chengbiao YangDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA.
Zhiqiang CaoDepartment of Chemical Engineering and Materials Science, Wayne State University, Detroit, MI, USA. zcao@wayne.edu.ORCID http://orcid.org/0000-0003-0114-2249
Wayne State University · US

Funding

A Novel Oral Insulin Enabling Safe and Efficient Gastrointestinal Transport and AbsorptionR01DK123293 · NIDDK · WAYNE STATE UNIVERSITY · PI CAO, ZHIQIANG · 2019 to 2022
$1.7M
A Novel Formulation Enabling Longevity of Subcutaneous Insulin InfusionDP2DK111910 · NIDDK · WAYNE STATE UNIVERSITY · PI CAO, ZHIQIANG · 2016 to 2016
$1.3M
NIDDK NIH HHS DP2 DK111910NIDDK NIH HHS R01 DK123293U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DP2DK111910U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) R01DK123293
6 · The paper itself

Abstract

Continuous subcutaneous insulin infusion (CSII) is an essential insulin replacement therapy in the management of diabetes. However, the longevity of clinical CSII is limited by skin complications, by impaired insulin absorption and by occlusions associated with the subcutaneous insertion of CSII catheters, which require replacement and rotation of the insertion site every few days. Here we show that a biodegradable zwitterionic gel covering the tip end of commercial off-the-shelf CSII catheters fully resolves early skin irritations, extends the longevity of catheters and improves the rate of insulin absorption (also with respect to conventional syringe-based subcutaneous injection) for longer than 6 months in diabetic mice, and by 11 days in diabetic minipigs (from 2 to 13 days, under standard CSII-wearing conditions of insulin pump therapy and in a continuous basal-plus-bolus-infusion setting). The implanted gel displayed anti-inflammatory and anti-foreign-body-reaction properties and promoted the local formation of new blood vessels. The gel is subcutaneously injected before the tip of catheter is inserted into it, and should be generally applicable to CSII catheters and other implantable devices.

Indexed as

GelsInsulinInsulin Infusion SystemsSwine, MiniatureAnimalsCathetersDiabetes Mellitus, ExperimentalMaleMiceMice, Inbred C57BLSwineGelsInsulin

Identifiers

PMID37884794
OpenAlexW4387965735

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.